Disitamab Biosimilar – Anti-ERBB2, EGFR2, CD340 mAb – Research Grade from ProteoGenix; catalogue PX-TA1574; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Disitamab Biosimilar, also known as Anti-ERBB2, EGFR2, CD340 mAb, is a highly potent monoclonal antibody that has gained significant attention in the field of cancer research. This biosimilar is specifically designed to target three important therapeutic targets – ERBB2, EGFR2, and CD340 – and has shown promising results in preclinical studies for the treatment of various cancers. In this article, we will explore the structure, activity, and potential applications of Disitamab Biosimilar in detail.
Disitamab Biosimilar is a recombinant humanized monoclonal antibody, meaning it is produced in a laboratory using genetic engineering techniques. It is composed of two heavy chains and two light chains, each containing a variable region and a constant region. The variable region is responsible for binding to its specific targets, while the constant region determines the antibody’s effector functions.
The antibody’s variable region is designed to specifically target three proteins – ERBB2, EGFR2, and CD340 – which are overexpressed in many types of cancer. This targeting mechanism makes Disitamab Biosimilar highly specific and selective, reducing the risk of off-target effects.
The primary activity of Disitamab Biosimilar is to inhibit the activity of ERBB2, EGFR2, and CD340 proteins, which are known to play a crucial role in cancer growth and progression. ERBB2 and EGFR2 are members of the epidermal growth factor receptor (EGFR) family, which are involved in cell proliferation, survival, and differentiation. CD340, also known as mesothelin, is a protein found on the surface of many cancer cells and is associated with tumor growth and metastasis.
By binding to these proteins, Disitamab Biosimilar blocks their signaling pathways and prevents them from promoting cancer cell growth. This inhibition can lead to the death of cancer cells or slow down their growth, making Disitamab Biosimilar a potential therapeutic option for various types of cancer.
Disitamab Biosimilar has shown promising results in preclinical studies for the treatment of different types of cancer, including breast, lung, ovarian, and pancreatic cancer. It has also been evaluated in combination with other cancer therapies, such as chemotherapy and radiation therapy, and has shown enhanced efficacy.
One of the most significant advantages of Disitamab Biosimilar is its potential to overcome resistance to other targeted therapies. Many cancers develop resistance to currently available treatments, making them challenging to treat. However, Disitamab Biosimilar targets multiple proteins, making it less likely for cancer cells to develop resistance to it.
In addition to its therapeutic potential, Disitamab Biosimilar is also being studied for diagnostic purposes. As it specifically targets ERBB2, EGFR2, and CD340, it can be used to detect the presence of these proteins in cancer cells, aiding in cancer diagnosis and monitoring treatment response.
Disitamab Biosimilar is a highly promising antibody that targets three important proteins involved in cancer growth and progression. Its unique structure and mechanism of action make it a potential therapeutic option for various types of cancer, including those that are resistant to currently available treatments. As research on Disitamab Biosimilar continues, it may prove to be a valuable addition to the arsenal of cancer therapies.
ProteoGenix catalogue number PX-TA1574. For research use only.
Target: Disitamab Biosimilar – Anti-ERBB2, EGFR2, CD340 mAb – Research Grade; Clonality: Monoclonal Antibody; Expression system: Mammalian cells; Purity: >85%; Buffer: PBS buffer PH7.5; Applications: ELISA, WB, Flow Cyt.
Available configurations: 50ug, 100ug, 1mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Target | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA |
|---|---|---|---|---|---|---|---|---|
| Disitamab Biosimilar – Anti-ERBB2, EGFR2, CD340 mAb – Research Grade |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
